Biblio Discovery — Demo Discovery Service

22 results for "David Hsiehchen"

Showing 1–20 · 1.17 seconds · RSS

  1. Journal Article Full text

    The Cooperative Landscape of Multinational Clinical Trials.

    David Hsiehchen; Magdalena Espinoza; Antony Hsieh

    PLoS ONE, Vol. 10 No. 6 · 2015 · English · DOAJ Scopus

    The scale and nature of cooperative efforts spanning geopolitical borders in clinical research have not been elucidated to date. In a cross-sectional study of 110,428 interventional trials registered in Clinicaltrials.gov, we characterized the evolution, trial demographics, and network properties…

    Also available at: PLOS

  2. Journal Article

    Female dermatology journal editors accepting pharmaceutical payments: An analysis of the Open Payments database, 2013 to 2018

    Waqas Haque, MPH, MPhil; Eman Haque; David Hsiehchen, MD

    International Journal of Women's Dermatology, Vol. 7 No. 4 · 2021 · English · DOAJ Scopus

    Background: Pharmaceutical payments may affect the interpretation of clinical research and prescribing patterns of physicians. Additionally, they may reflect gender disparities in academic dermatology with regard to social recognition and opportunities for career advancement. Objective: We examined…

  3. Journal Article

    Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab

    David Hsiehchen; Magdalena Espinoza; Prashanth Gowda et al.

    Journal for ImmunoTherapy of Cancer, Vol. 14 No. 1 · 2026 · English · DOAJ Scopus

    Background Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability/progression after atezolizumab…

  4. Journal Article

    Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial

    David Hsiehchen; Radhika Kainthla; Heather Kline et al.

    Nature Communications, Vol. 16 No. 1 · 2025 · English · DOAJ Scopus

    Abstract T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes and NK cells, and is a candidate compensatory immune checkpoint that may mediate anti-PD-1/L1 resistance in hepatocellular carcinoma (HCC). We conducted the phase 2 LIVERTI trial testing…

  5. Journal Article

    Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial

    David Hsiehchen; John H. Lohrey; Radhika Kainthla et al.

    Nature Communications, Vol. 17 No. 1 · 2026 · English · DOAJ Scopus

    Abstract T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor that promotes immune evasion, and dual blockade of TIGIT and PD-1 may restore antitumor immunity. Here we report the primary analysis of the biliary tract cancer cohort from a phase 2 trial (ClinicalTrials.gov…

  6. Journal Article

    Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers

    David Hsiehchen; Leslie Bucheit; Dong Yang et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Acquired resistance to systemic treatments is inevitable in most cancers, but the genetic basis for this in many cancer types has remained elusive due to constraints in obtaining tissue specimens longitudinally. In the management of gastrointestinal cancers, molecular profiling is…

  7. Journal Article

    DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

    David Hsiehchen; Antony Hsieh; Robert M. Samstein et al.

    Cell Reports Medicine, Vol. 1 No. 3 · 2020 · English · DOAJ Scopus

    Summary: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but prediction of their benefit is challenging. Neoantigens generated through impaired non-mismatch DNA repair may result in greater ICI activity. By analyzing 1,661 ICI-treated patients, we show that deletions and…

  8. Journal Article

    T-cell tolerant fraction as a predictor of immune-related adverse events

    Yang Xie; Shaheen Khan; Prithvi Raj et al.

    Journal for ImmunoTherapy of Cancer, Vol. 11 No. 8 · 2023 · English · DOAJ Scopus

    Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into the risk of irAEs. Here we evaluate a novel…

  9. Journal Article

    Association between immune-related adverse event timing and treatment outcomes

    David Hsiehchen; Abdul Rafeh Naqash; Magdalena Espinoza et al.

    OncoImmunology, Vol. 11 No. 1 · 2022 · English · DOAJ Scopus

    The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is unknown. We analyzed two independent cohorts…

  10. Journal Article

    Characteristics and clinical outcomes in young‐onset cholangiocarcinoma

    Sarah Reddy; Suleyman Yasin Goksu; Nina N. Sanford et al.

    Cancer Medicine, Vol. 12 No. 13 · 2023 · English · DOAJ Scopus

    Abstract Background While the incidence of cholangiocarcinoma is rising, little is known about young‐onset disease. We compared clinical characteristics and outcomes between patients with young‐onset cholangiocarcinoma, diagnosed between the ages of 18 and

  11. Journal Article

    Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

    Yang Xie; Vinita Popat; Shaheen Khan et al.

    Journal for ImmunoTherapy of Cancer, Vol. 9 No. 6 · 2021 · English · DOAJ Scopus

    Background Increased body mass index (BMI) has been associated with improved response to immune checkpoint inhibitors (ICIs) in multiple cancer types. We evaluated associations between BMI, ICI dosing strategy, and clinical outcomes.Methods We abstracted clinical data on patients with cancer…

  12. Journal Article

    The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

    David Hsiehchen; Muhammad S. Beg; Radhika Kainthla et al.

    Nature Communications, Vol. 15 No. 1 · 2024 · English · DOAJ Scopus

    Abstract Immune checkpoint inhibitors targeting PD-1/L1 have modest efficacy in hepatocellular carcinoma as single agents. Targeting membranous phosphatidylserine may induce pro-inflammatory and -immune stimulating effects that enhance immunotherapy activity. This hypothesis was tested in a…

  13. Journal Article

    Innate and adaptive immune features associated with immune-related adverse events

    Yang Liu; Tao Wang; Yang Xie et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 9 · 2025 · English · DOAJ Scopus

    Background While highly efficacious for numerous cancers, immune checkpoint inhibitors (ICIs) can cause unpredictable and potentially severe immune-related adverse events (irAEs), underscoring the need to understand irAE biology.Methods We used a multidimensional approach incorporating single-cell…

  14. Journal Article

    PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

    Kai Zimmer; Florian Kocher; Gerold Untergasser et al.

    npj Precision Oncology, Vol. 7 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling complex, is involved in DNA damage repair. Herein, we aimed to decipher the molecular landscape of PBRM1 mutated (mut) BTCs and to…

  15. Journal Article

    Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

    Mitchell S. von Itzstein; Yuqiu Yang; Yiqing Wang et al.

    Frontiers in Immunology, Vol. 15 · 2024 · English · DOAJ Scopus

    BackgroundA useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of treatment initiation, thereby providing information…

  16. Journal Article

    Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer

    Mitchell S. von Itzstein, MD; Jialiang Liu, PhD; Hong Mu-Mosley, PhD et al.

    JTO Clinical and Research Reports, Vol. 6 No. 1 · 2025 · English · DOAJ Scopus

    Introduction: Racial and ethnic disparities in the presentation and outcomes of lung cancer are widely known. To evaluate potential factors contributing to these observations, we measured systemic immune parameters in Black and White patients with lung cancer. Methods: Patients scheduled to receive…